Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $27 to $23.
Read original at benzingaStocks · News reference
8-K12B filing — Wave Life Sciences, Inc. (WVE)
Filed: 2026-08-07 AccNo: 0001193125-26-340430 Size: 972 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 7, 2026, 8:52 PM
- Checked
- Aug 7, 2026, 8:52 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $19
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $24 to $19.
Read original at benzingaB. Riley Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $22
B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $31 to $22.
Read original at benzinga